PARAGON 6-month Study data shows NEUROMARK® treatment benefits allergic and nonallergic rhinitis patients.
A successful round of fundraising has brought over €9 million to Neurent Medical as they develop a breakthrough therapy for Chronic Rhinitis
After closing a $25M Series B funding round, Neurent Medical prepares for commercialization of revolutionary in-office therapy.
Neurent Medical's expanded leadership team brings deep medical device and ENT-specific experience to the growing company.
Neurent Medical announces the commercial availability of NEUROMARK® System in limited U.S. markets.
In 2023, the Centers for Medicare and Medicaid Services (CMS) assigned a Category I Current Procedural Terminology (CPT®) reimbursement code for a breakthrough minimally invasive procedure for patients suffering from Chronic Rhinitis.
